Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

PURPOSE: Dasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose-optimization study. To better understand the super...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoning, Roy, Amit, Hochhaus, Andreas, Kantarjian, Hagop M, Chen, Tai-Tsang, Shah, Neil P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684141/
https://www.ncbi.nlm.nih.gov/pubmed/23788844
http://dx.doi.org/10.2147/CPAA.S42796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684141/
https://www.ncbi.nlm.nih.gov/pubmed/23788844
http://dx.doi.org/10.2147/CPAA.S42796

Ejemplares similares